Compare
ClearPoint Neuro, Inc. vs Cytosorbents Corp vs Retractable Technologies Inc vs Utah Medical Products Inc
| Latest fiscal year | ClearPoint Neuro, Inc. CLPT | Cytosorbents Corp CTSO | Retractable Technologies Inc RVP | Utah Medical Products Inc UTMD |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $36.97M | $37.06M | $38.27M | $38.52M |
| Revenue growth (YoY) | +17.8% | +4.1% | +15.8% | -5.8% |
| Gross margin | 61.4% | 71.5% | 0.1% | 57.1% |
| Operating margin | -65.4% | -39.8% | -55.3% | 29.6% |
| Net margin | -69.1% | -22.1% | -32.8% | 29.3% |
| Net income | -$25.54M | -$8.20M | -$12.57M | $11.29M |
| EPS (Diluted) | -$0.90 | -$0.13 | -$0.43 | $3.48 |
| Operating cash flow | -$23.93M | -$12.38M | -$7.06M | $14.69M |
| Free cash flow | -$24.45M | -$12.54M | n/a | $14.32M |
| Cash & equivalents | $45.92M | $6.25M | $2.59M | $85.76M |
| Total assets | $97.75M | $44.18M | $142.63M | $122.54M |
| Total liabilities | $69.73M | $38.28M | $68.26M | $3.27M |
| Shareholders' equity | $28.02M | $5.90M | $74.38M | $119.27M |
| Return on year-end equity | -91.1% | -138.9% | -16.9% | 9.5% |
| Shares outstanding | 29.37M | 62.80M | 29.94M | 3.19M |
Revenue, most recent five fiscal years
| Fiscal year | ClearPoint Neuro, Inc. | Cytosorbents Corp | Retractable Technologies Inc | Utah Medical Products Inc |
|---|---|---|---|---|
| Latest | $36.97M Ended 2025-12-31 | $37.06M Ended 2025-12-31 | $38.27M Ended 2025-12-31 | $38.52M Ended 2025-12-31 |
| 1 year earlier | $31.39M Ended 2024-12-31 | $35.59M Ended 2024-12-31 | $33.05M Ended 2024-12-31 | $40.90M Ended 2024-12-31 |
| 2 years earlier | $23.95M Ended 2023-12-31 | $31.08M Ended 2023-12-31 | $43.60M Ended 2023-12-31 | $50.22M Ended 2023-12-31 |
| 3 years earlier | $20.55M Ended 2022-12-31 | $34.69M Ended 2022-12-31 | $94.82M Ended 2022-12-31 | $52.28M Ended 2022-12-31 |
| 4 years earlier | $16.30M Ended 2021-12-31 | $43.17M Ended 2021-12-31 | $188.38M Ended 2021-12-31 | $49.05M Ended 2021-12-31 |